---

$4.79

-0.1050 ( -2.15% ) N/A

TransCode is a clinical-stage oncology company focused on treating metastatic disease. The company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-06-18	Sale	-70000.00	Calais Philippe
2024-06-18	Sale	-650000.00	Fitzgerald Thomas A
2024-06-18	Sale	-70000.00	Manting Erik
2024-06-18	Sale	-70000.00	Marquet Magda
2023-10-02	Buy	98000.00	Dudley Robert Michael
2023-10-02	Buy	49350.00	Fitzgerald Thomas A